Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase II, non-randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted (pre-) pandemic H5N1 influenza candidate vaccine following a heterologous prime-boost schedule (six months apart) in children aged 6 to 35 months

    Summary
    EudraCT number
    		 2011-004734-33
    Trial protocol
    		 Outside EU/EEA  
    Global end of trial date
    02 Nov 2012

    Results information
    Results version number
    		 v3(current)
    This version publication date
    02 Aug 2023
    First version publication date
    24 May 2015
    Other versions
    		 v1 , v2
    Version creation reason
    • Correction of full data set
    Corrections in safety section and age stratification added for immunogenicity endpoints.

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    109825
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01323946
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l’Institut 89, Rixensart, Belgium, B-1330
    Public contact
    Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    		 EMEA-000160-PIP01-07
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Feb 2013
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    22 Jun 2012
    Global end of trial reached?
    Yes
    Global end of trial date
    02 Nov 2012
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess whether a heterologous booster dose of H5N1 (A/turkey/Turkey/1/2005) haemagglutinin (HA) given 6 months following a 2-dose primary vaccination series with H5N1 (A/Indonesia/05/2005) HA elicits an antibody response that meets the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) guidance targets for pre-pandemic vaccine seroconversion rate (SCR), seroprotection rate (SPR) and mean geometric increase (MGI) based on haemagglutination inhibition (HI) responses to A/turkey/Turkey/1/2005 (H5N1) ten days following booster vaccination.
    Protection of trial subjects
    Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    18 Apr 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Singapore: 84
    Country: Number of subjects enrolled
    Australia: 29
    Worldwide total number of subjects
    113
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    80
    Children (2-11 years)
    33
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

    Period 1
    Period 1 title
    Overall (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 GSK1562902A 6 to 12 M Group
    Arm description
    		 Subjects between 6 and 12 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK1562902A vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    The vaccine was administered intramuscularly in the anterolateral thigh.

    Arm title
    		 GSK1562902A 12 to 24 M Group
    Arm description
    		 Subjects between 12 and 24 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK1562902A vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    The vaccine was administered intramuscularly in the deltoid region of arm.

    Arm title
    		 GSK1562902A 24 to 36 M Group
    Arm description
    		 Subjects between 24 and 36 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK1562902A vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    The vaccine was administered intramuscularly in the deltoid region of arm.

    Number of subjects in period 1
    		GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group
    Started
    46
    34
    33
    Completed
    43
    31
    33
    Not completed
    3
    3
    0
         Consent withdrawn by subject
    3
    3
    -

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    GSK1562902A 6 to 12 M Group
    Reporting group description
    		 Subjects between 6 and 12 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Reporting group title
    GSK1562902A 12 to 24 M Group
    Reporting group description
    		 Subjects between 12 and 24 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Reporting group title
    GSK1562902A 24 to 36 M Group
    Reporting group description
    		 Subjects between 24 and 36 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Reporting group values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group Total
    Number of subjects
    		 46 34 33 113
    Age categorical
    Units: Subjects
        In utero
    		 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0
        Newborns (0-27 days)
    		 0
        Infants and toddlers (28 days-23 months)
    		 0
        Children (2-11 years)
    		 0
        Adolescents (12-17 years)
    		 0
        Adults (18-64 years)
    		 0
        From 65-84 years
    		 0
        85 years and over
    		 0
    Age continuous
    Units: months
        arithmetic mean (standard deviation)
    		 8.3 ± 1.56 16.1 ± 3.44 29.6 ± 3.38 -
    Gender categorical
    Units: Subjects
        Female
    		 25 19 19 63
        Male
    		 21 15 14 50
    Race/Ethnicity characteristic
    Units: Subjects
        Asian-South East Asian
    		 33 25 22 80
        Asian-East Asian Heritage
    		 0 1 0 1
        White-caucasian/european heritage
    		 12 8 9 29
        Unspecified
    		 1 0 2 3
    Subject analysis sets

    Subject analysis set title
    GSK1562902A Group
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Subjects received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Subject analysis sets values
    		 GSK1562902A Group
    Number of subjects
    113
    Age categorical
    Units: Subjects
        In utero
        Preterm newborn infants (gestational age < 37 wks)
        Newborns (0-27 days)
        Infants and toddlers (28 days-23 months)
        Children (2-11 years)
        Adolescents (12-17 years)
        Adults (18-64 years)
        From 65-84 years
        85 years and over
    Age continuous
    Units: months
        arithmetic mean (standard deviation)
    16.9 ± 9.29
    Gender categorical
    Units: Subjects
        Female
    63
        Male
    50
    Race/Ethnicity characteristic
    Units: Subjects
        Asian-South East Asian
        Asian-East Asian Heritage
        White-caucasian/european heritage
        Unspecified

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    GSK1562902A 6 to 12 M Group
    Reporting group description
    		 Subjects between 6 and 12 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Reporting group title
    GSK1562902A 12 to 24 M Group
    Reporting group description
    		 Subjects between 12 and 24 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Reporting group title
    GSK1562902A 24 to 36 M Group
    Reporting group description
    		 Subjects between 24 and 36 months of age, who received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Subject analysis set title
    GSK1562902A Group
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Subjects received 2 primary doses of A/Indonesia/05/2005 H5N1 vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 H5N1 vaccine on Day 182.

    Primary: 1. Number of seroconverted subjects in terms of H5N1 antibodies against A/Turkey/Turkey/1/2005 H5N1 Virus Strain

    		 Close Top of page
    End point title
    		 1. Number of seroconverted subjects in terms of H5N1 antibodies against A/Turkey/Turkey/1/2005 H5N1 Virus Strain [1]
    End point description
    A seroconverted subject is defined as a subject that had either a pre-vaccination (Day 0) titer < 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer on Day 192.
    End point type
    Primary
    End point timeframe
    At Day 192
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was descriptive, thus not statistical analysis was performed.
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    33
    21
    29
    83
    Units: Subjects
        A/turkey/Turkey/01/2005.HA [Day 192]
    33
    21
    29
    83
    No statistical analyses for this end point

    Primary: 2. Geometric mean of the within-subject ratios

    		 Close Top of page
    End point title
    		 2. Geometric mean of the within-subject ratios [2]
    End point description
    HI antibody concentration against Flu A/Turk/01/05 (H5N1)
    End point type
    Primary
    End point timeframe
    At Day 192
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was descriptive, thus not statistical analysis was performed.
    End point values
    		 GSK1562902A Group
    Number of subjects analysed
    83
    Units: Titers
    geometric mean (confidence interval 95%)
        Flu A/Turk/01/05 (H5N1).HA [Day 192]
    357.7 (302.4 to 423.2)
    No statistical analyses for this end point

    Primary: 3. Number of seroprotected subjects for HI antibodies

    		 Close Top of page
    End point title
    		 3. Number of seroprotected subjects for HI antibodies [3]
    End point description
    HI antibody concentration against A/turkey/Turkey/01/2005
    End point type
    Primary
    End point timeframe
    At Day 192
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was descriptive, thus not statistical analysis was performed.
    End point values
    		 GSK1562902A Group
    Number of subjects analysed
    83
    Units: Subjects
        A/turkey/Turkey/01/2005.HA [Day192]
    83
    No statistical analyses for this end point

    Secondary: 4. Hemagglutination Inhibition (HI) antibody titers against the A/indonesia/05/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 4. Hemagglutination Inhibition (HI) antibody titers against the A/indonesia/05/2005 H5N1 virus strain
    End point description
    Titers were presented as geometric mean titers (GMTs). Analyses were done by age stratum and overall.
    End point type
    Secondary
    End point timeframe
    At Day 0, Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Titers
    geometric mean (confidence interval 95%)
        A/Indonesia/05/2005.HA [Day 0]
    5 (5 to 5)
    5 (5 to 5)
    5 (5 to 5)
    5 (5 to 5)
        A/Indonesia/05/2005.HA [Day 42]
    945.2 (745.8 to 1197.9)
    1336.7 (990.3 to 1804.2)
    1044.7 (832.6 to 1310.9)
    1078.6 (935.3 to 1243.7)
        A/Indonesia/05/2005.HA [Day 182]
    160.0 (125.4 to 204.2)
    147.3 (113.2 to 191.7)
    133.7 (113.1 to 158.1)
    147.2 (129.6 to 167.1)
        A/Indonesia/05/2005.HA [Day 192]
    2163.8 (1772.7 to 2641.4)
    1534.7 (1108.1 to 2125.5)
    1606.2 (1254.3 to 2056.9)
    1787.6 (1552.4 to 2058.3)
        A/Indonesia/05/2005.HA [Day 364]
    1465.4 (1168.2 to 1838.1)
    1055.8 (769.2 to 1449.1)
    668.4 (505.2 to 884.2)
    1043.3 (886.1 to 1228.4)
    No statistical analyses for this end point

    Secondary: 5. HI antibody titers against the A/Turkey/01/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 5. HI antibody titers against the A/Turkey/01/2005 H5N1 virus strain
    End point description
    Titers were presented as geometric mean titers (GMTs). Analyses were done by age stratum and overall.
    End point type
    Secondary
    End point timeframe
    At Day 0, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Titers
    geometric mean (confidence interval 95%)
        A/turkey/Turkey/01/2005.HA [Day 0]
    5.8 (5.2 to 6.5)
    5.8 (4.8 to 6.9)
    5.5 (4.7 to 64)
    5.7 (5.2 to 6.2)
        A/turkey/Turkey/01/2005.HA [Day 182]
    95.7 (75.5 to 121.1)
    84.1 (65.5 to 108.1)
    86.1 (73.8 to 100.4)
    89.3 (79.1 to 100.7)
        A/turkey/Turkey/01/2005.HA [Day 192]
    2454.6 (1935.7 to 3112.6)
    1810.2 (1207.1 to 2714.7)
    1767.4 (1403.0 to 2226.3)
    2026.2 (1731.3 to 2371.3)
        A/turkey/Turkey/01/2005.HA [Day 364]
    1810.1 (1466.6 to 2234.0)
    1263.8 (929.1 to 1718.0)
    803.4 (609.7 to 1058.8)
    1266.8 (1080.6 to 1485)
    No statistical analyses for this end point

    Secondary: 6. Number of seropositive subjects in terms of H5N1 HI antibodies against A/Indonesia/05/2005 virus strain

    		 Close Top of page
    End point title
    		 6. Number of seropositive subjects in terms of H5N1 HI antibodies against A/Indonesia/05/2005 virus strain
    End point description
    A seropositive subject is defined as a subject with a serum H5N1 HI antibody titer >=1:10.
    End point type
    Secondary
    End point timeframe
    At Day 0, Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Subjects
        A/Indonesia/05/2005.HA [Day 0]
    0
    0
    0
    0
        A/Indonesia/05/2005.HA [Day 42]
    32
    24
    29
    85
        A/Indonesia/05/2005.HA [Day 182]
    33
    24
    29
    83
        A/Indonesia/05/2005.HA [Day 192]
    33
    21
    29
    83
        A/Indonesia/05/2005.HA [Day 364]
    41
    27
    32
    100
    No statistical analyses for this end point

    Secondary: 7. Number of seropositive subjects in terms of H5N1 HI antibodies against A/turkey/Turkey/01/2005 virus strain

    		 Close Top of page
    End point title
    		 7. Number of seropositive subjects in terms of H5N1 HI antibodies against A/turkey/Turkey/01/2005 virus strain
    End point description
    A seropositive subject is defined as a subject with a serum H5N1 HI antibody titer >=1:10.
    End point type
    Secondary
    End point timeframe
    At Day 0, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Subjects
        A/turkey/Turkey/01/2005.HA [Day 0]
    6
    3
    2
    11
        A/turkey/Turkey/01/2005.HA [Day 182]
    33
    21
    29
    83
        A/turkey/Turkey/01/2005.HA [Day 192]
    33
    21
    29
    83
        A/turkey/Turkey/01/2005.HA [Day 364]
    41
    27
    32
    100
    No statistical analyses for this end point

    Secondary: 8. Number of seroconverted subjects in terms of H5N1 HI antibodies against A/Indonesia/05/2005 virus strain

    		 Close Top of page
    End point title
    		 8. Number of seroconverted subjects in terms of H5N1 HI antibodies against A/Indonesia/05/2005 virus strain
    End point description
    A seroconverted subject is defined as a subject who had either a pre-vaccination (Day 0) titer < 1:10 and a post-vaccination titer >=1:40, or a pre vaccination titer >=1"10 and at aleast a 4-fold increase in post-vaccination titer.
    End point type
    Secondary
    End point timeframe
    At Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Subjects
        A/Indonesia/05/2005.HA [Day 42]
    32
    24
    29
    85
        A/Indonesia/05/2005.HA [Day 182]
    32
    21
    29
    83
        A/Indonesia/05/2005.HA [Day 192]
    33
    21
    29
    83
        A/Indonesia/05/2005.HA [Day 364]
    41
    27
    32
    100
    No statistical analyses for this end point

    Secondary: 9. Number of seroconverted subjects in terms of H5N1 HI antibodies against A/turkey/Turkey/01/2005 virus strain

    		 Close Top of page
    End point title
    		 9. Number of seroconverted subjects in terms of H5N1 HI antibodies against A/turkey/Turkey/01/2005 virus strain
    End point description
    A seroconverted subject is defined as a subject who had either a pre-vaccination (Day 0) titer < 1:10 and a post-vaccination titer >=1:40, or a pre vaccination titer >=1:10 and at least a 4-fold increase in post-vaccination titer. Data for Day 192 are presented under Primary Endpoints.
    End point type
    Secondary
    End point timeframe
    At Day 182 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    26
    32
    99
    Units: Subjects
        A/turkey/Turkey/1/2005 H5N1 (Day 182)
    31
    20
    28
    83
        A/turkey/Turkey/1/2005 H5N1 (Day 364)
    41
    26
    28
    95
    No statistical analyses for this end point

    Secondary: 10.Number of seroprotected subjects in terms of H5N1 HI antibodies against A/Indonesia/05/2005 virus strain

    		 Close Top of page
    End point title
    		 10.Number of seroprotected subjects in terms of H5N1 HI antibodies against A/Indonesia/05/2005 virus strain
    End point description
    A seroprotected subject is defined as a subject with a serum H5N1 HI antibody titer ≥1:40.
    End point type
    Secondary
    End point timeframe
    At Day 0, Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Subjects
        A/Indonesia/05/2005 H5N1.HA [Day 0]
    0
    0
    0
    0
        A/Indonesia/05/2005 H5N1.HA [Day 42]
    32
    24
    29
    85
        A/Indonesia/05/2005 H5N1.HA [Day 182]
    32
    21
    29
    82
        A/Indonesia/05/2005 H5N1.HA [Day 192]
    33
    21
    29
    83
        A/Indonesia/05/2005 H5N1.HA [Day 364]
    41
    27
    32
    100
    No statistical analyses for this end point

    Secondary: 14. Number of seroconverted subjects in terms of HI antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 14. Number of seroconverted subjects in terms of HI antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain
    End point description
    Booster seroconversion is defined as follows: For seronegative subjects at pre-booster (Day 182), antibody titer ≥1:40 at post-booster time point(s). For seropositive subjects at pre-booster (Day 182), antibody titer at post-booster time point(s) ≥4-fold the pre-booster antibody titer.
    End point type
    Secondary
    End point timeframe
    At Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    26
    32
    99
    Units: Subjects
        A/turkey/Turkey/01/2005.HA [Day 192]
    32
    21
    29
    82
        A/turkey/Turkey/01/2005.HA [Day 364]
    41
    26
    28
    95
    No statistical analyses for this end point

    Secondary: 15. Booster Factor in terms of neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 15. Booster Factor in terms of neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain
    End point description
    Booster Factor was defined as the geometric mean of the within-subject ratios of the post-booster vaccination reciprocal HI titre to the pre-booster (Day 182) reciprocal titer.
    End point type
    Secondary
    End point timeframe
    At Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    26
    32
    99
    Units: Titers
    geometric mean (confidence interval 95%)
        A/turkey/Turkey/01/2005.HA [Day 192]
    25.7 (18.4 to 35.7)
    21.5 (16.4 to 28.2)
    20.5 (16.2 to 26.1)
    22.7 (19.3 to 26.8)
        A/turkey/Turkey/01/2005.HA [Day 364]
    19.9 (15.2 to 26.1)
    16.4 (12.6 to 21.4)
    9.5 (7.2 to 12.5)
    14.9 (12.6 to 17.6)
    No statistical analyses for this end point

    Secondary: 16.Number of seropositive subjects in terms of serum neutralizing antibodies against A/Indonesia/05/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 16.Number of seropositive subjects in terms of serum neutralizing antibodies against A/Indonesia/05/2005 H5N1 virus strain
    End point description
    A seropositive subject is defined as a subject with serum neutralizing antibody titers ≥ 1:28
    End point type
    Secondary
    End point timeframe
    Day 0, Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    37
    27
    31
    95
    Units: Subjects
        Flu A/Ind/05/05 (H5N1) [Day 0]
    0
    0
    1
    1
        Flu A/Ind/05/05 (H5N1) [Day 42]
    24
    21
    25
    70
        Flu A/Ind/05/05 (H5N1) [Day 182]
    32
    21
    28
    81
        Flu A/Ind/05/05 (H5N1) [Day 192]
    33
    21
    29
    83
        Flu A/Ind/05/05 (H5N1) [Day 364]
    37
    27
    31
    95
    No statistical analyses for this end point

    Secondary: 17. Number of seropositive subjects in terms of serum neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 17. Number of seropositive subjects in terms of serum neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain
    End point description
    A seropositive subject is defined as a subject with serum neutralizing antibody titers ≥ 1:28.
    End point type
    Secondary
    End point timeframe
    Day 0, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    37
    27
    31
    95
    Units: Subjects
        Flu A/Turk/01/05 (H5N1) [Day 0]
    0
    0
    0
    0
        Flu A/Turk/01/05 (H5N1) [Day 182]
    32
    21
    28
    81
        Flu A/Turk/01/05 (H5N1) [Day 192]
    33
    21
    29
    83
        Flu A/Turk/01/05 (H5N1) [Day 364]
    37
    27
    31
    95
    No statistical analyses for this end point

    Secondary: 18. Serum neutralizing antibody titers in terms of neutralizing antibodies against A/Indonesia/05/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 18. Serum neutralizing antibody titers in terms of neutralizing antibodies against A/Indonesia/05/2005 H5N1 virus strain
    End point description
    Titers were presented as geometric mean titers (GMTs).
    End point type
    Secondary
    End point timeframe
    Day 0, Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    37
    27
    31
    95
    Units: Titers
    geometric mean (confidence interval 95%)
        Flu A/Ind/05/05 (H5N1) [Day 0]
    0 (0 to 0)
    0 (0 to 0)
    14.4 (13.6 to 15.3)
    14.1 (13.9 to 14.4)
        Flu A/Ind/05/05 (H5N1) [Day 42]
    1785.9 (1168.6 to 2729.5)
    2080.4 (1422.8 to 3041.7)
    1755.2 (1191.3 to 2586.1)
    1858 (1491.3 to 2315)
        Flu A/Ind/05/05 (H5N1) [Day 182]
    526.6 (397.1 to 698.2)
    483.3 (333.1 to 701.3)
    353.4 (273.7 to 456.2)
    448.7 (379 to 531.2)
        Flu A/Ind/05/05 (H5N1) [Day 192]
    12667.0 (10522.9 to 15248.1)
    11031.5 (8157.8 to 14917.5)
    9883.1 (7631.9 to 12798.4)
    11215.7 (9797.4 to 12839.2)
        Flu A/Ind/05/05 (H5N1) [Day 364]
    6420.9 (4851.0 to 8498.9)
    4730.9 (3237.5 to 6913.0)
    2422.9 (1674.9 to 3504.9)
    4283.3 (3485.8 to 5263.2)
    No statistical analyses for this end point

    Secondary: 19. Serum neutralizing antibody titers in terms of neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 19. Serum neutralizing antibody titers in terms of neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain
    End point description
    Titers were presented as geometric mean titers (GMTs).
    End point type
    Secondary
    End point timeframe
    Day 0, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    37
    27
    31
    95
    Units: Titers
    geometric mean (confidence interval 95%)
        Flu A/Turk/01/05 (H5N1) [Day 0]
    0 (0 to 0)
    0 (0 to 0)
    0 (0 to 0)
    0 (0 to 0)
        Flu A/Turk/01/05 (H5N1) [Day 182]
    137.5 (108.3 to 174.7)
    124.9 (104.3 to 149.5)
    113.2 (96.2 to 133.2)
    125.4 (111.6 to 140.8)
        Flu A/Turk/01/05 (H5N1) [Day 192]
    7391.0 (5117.8 to 10674.0)
    5464.2 (3426.9 to 8712.7)
    3349.4 (2249.8 to 4986.4)
    5192.9 (4101.3 to 6575.1)
        Flu A/Turk/01/05 (H5N1) [Day 364]
    4149.7 (3028.8 to 5685.4)
    3030.8 (2036.2 to 4511.4)
    1317.8 (898.4 to 1933.0)
    2610.2 (2085.3 to 3267.2)
    No statistical analyses for this end point

    Secondary: 20. Number of subjects with a vaccine response in terms of serum neutralizing antibodies against A/Indonesia/05/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 20. Number of subjects with a vaccine response in terms of serum neutralizing antibodies against A/Indonesia/05/2005 H5N1 virus strain
    End point description
    Vaccine response is defined as: For initially seronegative subjects, neutralizing antibody titer ≥ 1:56 at the considered time point after vaccination For initially seropositive subjects, neutralizing antibody titer ≥ 4 fold from pre-vaccination (Day 0).
    End point type
    Secondary
    End point timeframe
    At Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    33
    25
    25
    83
    Units: Subjects
        Flu A/Ind/05/05 (H5N1) [Day 42]
    22
    19
    21
    62
        Flu A/Ind/05/05 (H5N1) [Day 182]
    28
    19
    22
    70
        Flu A/Ind/05/05 (H5N1) [Day 192]
    29
    19
    24
    72
        Flu A/Ind/05/05 (H5N1) [Day 364]
    33
    25
    25
    83
    No statistical analyses for this end point

    Secondary: 21. Number of subjects with a vaccine response in terms of serum neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 21. Number of subjects with a vaccine response in terms of serum neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain
    End point description
    Vaccine response is defined as: For initially seronegative subjects, neutralizing antibody titer ≥ 1:56 at the considered time point after vaccination For initially seropositive subjects, neutralizing antibody titer ≥ 4 fold from pre-vaccination (Day 0)
    End point type
    Secondary
    End point timeframe
    At Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    33
    25
    25
    83
    Units: Subjects
        Flu A/Turk/01/05 (H5N1) Ab [Day 182]
    22
    17
    19
    58
        Flu A/Turk/01/05 (H5N1) Ab [Day 192]
    29
    19
    24
    72
        Flu A/Turk/01/05 (H5N1) Ab [Day 364]
    33
    25
    25
    83
    No statistical analyses for this end point

    Secondary: 22. Number of subjects with a booster vaccine response in terms of serum neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 22. Number of subjects with a booster vaccine response in terms of serum neutralizing antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain
    End point description
    Booster vaccine response is defined as: For seronegative subjects at Day 182, neutralizing antibody titers ≥ 1:56 at the considered time point after vaccination For seropositive subjects at Day 182, neutralizing antibody titers ≥ 4 fold from pre-vaccination (Day 182)
    End point type
    Secondary
    End point timeframe
    At Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    32
    24
    23
    79
    Units: Subjects
        Flu A/Turk/01/05 (H5N1) [Day 192]
    27
    19
    23
    69
        Flu A/Turk/01/05 (H5N1) [Day 364]
    32
    22
    22
    76
    No statistical analyses for this end point

    Secondary: 23. Number of subjects with any and Grade 3 solicited local symptoms

    		 Close Top of page
    End point title
    		 23. Number of subjects with any and Grade 3 solicited local symptoms
    End point description
    Solicited local symptoms assigned were pain, swelling and redness. Any was defined as occurrence of any local symptom regardless of intensity grade; Grade 3 pain was defined as cried when limb was moved spontaneously painful.
    End point type
    Secondary
    End point timeframe
    During the 7-day post-vaccination period following each dose and across doses (Day 0 - Day 7, Day 21 - Day 28, Day 182 - Day 189)
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    46
    33
    33
    112
    Units: Subjects
        Any Pain Dose 1
    14
    5
    13
    32
        Grade 3 Pain Dose 1
    2
    0
    1
    3
        Any Redness Dose 1
    2
    0
    2
    4
        Grade 3 Redness Dose 1
    0
    0
    0
    0
        Any Swelling Dose 1
    1
    1
    1
    3
        Grade 3 Swelling Dose 1
    0
    0
    0
    0
        Any Pain Dose 2
    10
    13
    14
    37
        Grade 3 Pain Dose 2
    0
    0
    1
    1
        Any Redness Dose 2
    3
    2
    1
    6
        Grade 3 Redness Dose 2
    0
    0
    0
    0
        Any Swelling Dose 2
    2
    2
    0
    4
        Grade 3 Swelling Dose 2
    0
    0
    0
    0
        Any Pain Dose 3
    20
    15
    18
    53
        Grade 3 Pain Dose 3
    3
    1
    3
    7
        Any Redness Dose 3
    11
    5
    2
    18
        Grade 3 Redness Dose 3
    0
    0
    0
    0
        Any Swelling Dose 3
    5
    5
    1
    11
        Grade 3 Swelling Dose 3
    0
    0
    0
    0
        Any Pain Across doses
    26
    19
    21
    66
        Grade 3 Pain Across doses
    4
    1
    5
    10
        Any Redness Across doses
    13
    6
    3
    22
        Grade 3 Redness Across doses
    0
    0
    0
    0
        Any Swelling Across doses
    6
    6
    1
    13
        Grade 3 Swelling Across doses
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: 24. Number of subjects with any, Grade 3 and related solicited general symptoms

    		 Close Top of page
    End point title
    		 24. Number of subjects with any, Grade 3 and related solicited general symptoms
    End point description
    Solicited general symptoms assessed were diarrhoea/ vomiting, drowsiness, irritability/ fussiness, loss of appetite, fever (axillary). Any= occurrence of any general symptom regardless of intensity grade and relationship to the vaccine. Irritability/ fussiness grade 3=crying that could not be comforted/ prevented normal activity; Drowsiness grade 3= drowsiness that prevented normal activity; Loss of appetite grade 3= did not eat at all; Diarrhoea/ vomiting grade 3= diarrhoea/ vomiting that prevented normal activity; Related= general symptom assessed by the investigator as causally related to the study vaccination.
    End point type
    Secondary
    End point timeframe
    During the 7-day post-vaccination period following each dose and across doses (Day 0 - Day 7, Day 21 - Day 28, Day 182 - Day 189)
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    46
    33
    33
    112
    Units: Subjects
        Any Diarrhoea/vomiting Dose 1
    10
    6
    3
    19
        Grade 3 Diarrhoea/vomiting Dose 1
    1
    1
    0
    2
        Related Diarrhoea/vomiting Dose 1
    6
    1
    2
    9
        Any Drowsiness Dose 1
    10
    9
    5
    24
        Grade 3 Drowsiness Dose 1
    1
    0
    0
    1
        Related Drowsiness Dose 1
    8
    7
    5
    20
        Any Irritability/fussiness Dose 1
    21
    14
    9
    44
        Grade 3 Irritability/fussiness Dose 1
    3
    0
    0
    3
        Related Irritability/fussiness Dose 1
    19
    10
    8
    37
        Any Loss of appetite Dose 1
    9
    12
    6
    27
        Grade 3 Loss of appetite Dose 1
    0
    1
    0
    1
        Related Loss of appetite Dose 1
    5
    8
    5
    18
        Any Fever (Axillary) Dose 1
    4
    6
    4
    14
        Grade 3 Fever (Axillary) Dose 1
    0
    2
    0
    2
        Related Fever (Axillary) Dose 1
    3
    5
    3
    11
        Any Diarrhoea/vomiting Dose 2
    8
    3
    2
    13
        Grade 3 Diarrhoea/vomiting Dose 2
    0
    0
    0
    0
        Related Diarrhoea/vomiting Dose 2
    7
    2
    1
    10
        Any Drowsiness Dose 2
    8
    12
    7
    27
        Grade 3 Drowsiness Dose 2
    1
    1
    1
    3
        Related Drowsiness Dose 2
    8
    10
    7
    25
        Any Irritability/fussiness Dose 2
    14
    17
    10
    41
        Grade 3 Irritability/fussiness Dose 2
    1
    3
    0
    4
        Related Irritability/fussiness Dose 2
    13
    15
    10
    38
        Any Loss of appetite Dose 2
    8
    6
    9
    23
        Grade 3 Loss of appetite Dose 2
    0
    1
    0
    1
        Related Loss of appetite Dose 2
    8
    5
    8
    21
        Any Fever (Axillary) Dose 2
    14
    12
    10
    36
        Grade 3 Fever (Axillary) Dose 2
    2
    3
    1
    6
        Related Fever (Axillary) Dose 2
    14
    12
    10
    36
        Any Diarrhoea/vomiting Dose 3
    10
    3
    3
    16
        Grade 3 Diarrhoea/vomiting Dose 3
    1
    0
    0
    1
        Related Diarrhoea/vomiting Dose 3
    9
    2
    1
    12
        Any Drowsiness Dose 3
    16
    6
    10
    32
        Grade 3 Drowsiness Dose 3
    2
    0
    1
    3
        Related Drowsiness Dose 3
    16
    6
    7
    29
        Any Irritability/fussiness Dose 3
    28
    15
    11
    54
        Grade 3 Irritability/fussiness Dose 3
    7
    0
    2
    9
        Related Irritability/fussiness Dose 3
    26
    15
    10
    51
        Any Loss of appetite Dose 3
    16
    12
    9
    37
        Grade 3 Loss of appetite Dose 3
    2
    0
    2
    4
        Related Loss of appetite Dose 3
    15
    12
    7
    34
        Any Fever (Axillary) Dose 3
    20
    15
    19
    54
        Grade 3 Fever (Axillary) Dose 3
    3
    5
    3
    11
        Related Fever (Axillary) Dose 3
    19
    15
    18
    52
        Any Diarrhoea/vomiting Across doses
    17
    11
    7
    35
        Grade 3 Diarrhoea/vomiting Across doses
    1
    1
    0
    2
        Related Diarrhoea/vomiting Across doses
    14
    5
    3
    22
        Any Drowsiness Across doses
    22
    18
    12
    52
        Grade 3 Drowsiness Across doses
    3
    1
    2
    6
        Related Drowsiness Across doses
    21
    17
    12
    50
        Any Irritability/fussiness Across doses
    35
    23
    15
    73
        Grade 3 Irritability/fussiness Across doses
    10
    3
    2
    15
        Related Irritability/fussiness Across doses
    35
    23
    14
    72
        Any Loss of appetite Across doses
    22
    18
    14
    54
        Grade 3 Loss of appetite Across doses
    2
    2
    2
    6
        Related Loss of appetite Across doses
    19
    17
    14
    50
        Any Fever (Axillary) Across doses
    29
    19
    21
    69
        Grade 3 Fever (Axillary) Across doses
    5
    8
    4
    17
        Related Fever (Axillary) Across doses
    28
    19
    20
    67
    No statistical analyses for this end point

    Secondary: 25. Number of subjects with medically-attended events (MAEs)

    		 Close Top of page
    End point title
    		 25. Number of subjects with medically-attended events (MAEs)
    End point description
    MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. Analysis of intensity and relationship to vaccination of MAEs was not performed.
    End point type
    Secondary
    End point timeframe
    During the entire study period (from Day 0 to Day 364)
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    46
    34
    33
    113
    Units: Subjects
        Any MAE(s)
    29
    19
    20
    68
    No statistical analyses for this end point

    Secondary: 26. Number of subjects with potential immune-mediated disease (pIMDs)

    		 Close Top of page
    End point title
    		 26. Number of subjects with potential immune-mediated disease (pIMDs)
    End point description
    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
    End point type
    Secondary
    End point timeframe
    During the entire study period (from day 0 to Day 364)
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    46
    34
    33
    113
    Units: Subjects
        Any pIMDs
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: 27. Number of subjects with unsolicited adverse events (AEs)

    		 Close Top of page
    End point title
    		 27. Number of subjects with unsolicited adverse events (AEs)
    End point description
    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. "Grade 3" was defined as an AE which prevented normal, everyday activities. "Related" was defined as an AE assessed by the investigator as causally related to the study vaccination.
    End point type
    Secondary
    End point timeframe
    During a 21 day follow-up period after each vaccination (Day 0 - Day 21, Day 21 - Day 42, Day 182 - Day 203)
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    46
    34
    33
    113
    Units: Subjects
        Any AE(s)
    29
    19
    24
    72
        Grade 3 AE(s)
    5
    3
    2
    10
        Related AE(s)
    13
    5
    7
    25
    No statistical analyses for this end point

    Secondary: 28. Number of subjects with unsolicited adverse events (AEs)

    		 Close Top of page
    End point title
    		 28. Number of subjects with unsolicited adverse events (AEs)
    End point description
    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. "Grade 3" was defined as an AE which prevented normal, everyday activities. "Related" was defined as an AE assessed by the investigator as causally related to the study vaccination.
    End point type
    Secondary
    End point timeframe
    During a Day 84 follow-up period after each vaccination (Day 0 - Day 84, Day 21 - Day 105, Day 182 - Day 266)
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    46
    34
    33
    113
    Units: Subjects
        Any AE(s)
    32
    23
    22
    77
        Grade 3 AE(s)
    4
    4
    2
    10
        Related AE(s)
    9
    3
    6
    18
    No statistical analyses for this end point

    Secondary: 29. Number of subjects with serious adverse events (SAEs)

    		 Close Top of page
    End point title
    		 29. Number of subjects with serious adverse events (SAEs)
    End point description
    Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
    End point type
    Secondary
    End point timeframe
    During the entire study period (from Day 0 to 364)
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    46
    34
    33
    113
    Units: Subjects
        SAEs
    5
    4
    0
    9
    No statistical analyses for this end point

    Secondary: 11. Number of seroprotected subjects in terms of H5N1 HI antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 11. Number of seroprotected subjects in terms of H5N1 HI antibodies against A/turkey/Turkey/1/2005 H5N1 virus strain
    End point description
    A seroprotected subject is defined as a subject with a serum H5N1 HI antibody titer ≥1:40. Data for Day 192 are presented under Primary Outcome Measures.
    End point type
    Secondary
    End point timeframe
    Day 0, Day 182 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Count of Participants
        A/turkey/Turkey/1/2005 H5N1.HA [Day 0]
    0
    0
    1
    1
        A/turkey/Turkey/1/2005 H5N1.HA [Day 182]
    31
    21
    29
    81
        A/turkey/Turkey/1/2005 H5N1.HA [Day 364]
    41
    27
    32
    100
    No statistical analyses for this end point

    Secondary: 12. Mean Geometric Change in terms of H5N1 HI antibodies against A/Indonesia/05/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 12. Mean Geometric Change in terms of H5N1 HI antibodies against A/Indonesia/05/2005 H5N1 virus strain
    End point description
    Mean Geometric Change is defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer (i.e. post-vaccination divided by pre-vaccination titer).
    End point type
    Secondary
    End point timeframe
    At Day 42, Day 182, Day 192 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    27
    32
    100
    Units: Subjects
        A/Indonesia/05/2005 H5N1.HA [Day 42]
    32
    24
    29
    85
        A/Indonesia/05/2005 H5N1.HA [Day 182]
    33
    21
    29
    83
        A/Indonesia/05/2005 H5N1.HA [Day 192]
    33
    21
    29
    83
        A/Indonesia/05/2005 H5N1.HA [Day 364]
    41
    27
    32
    100
    No statistical analyses for this end point

    Secondary: 13. Mean Geometric Change in terms of H5N1 HI antibodies against A/turkey/Turkey/01/2005 H5N1 virus strain

    		 Close Top of page
    End point title
    		 13. Mean Geometric Change in terms of H5N1 HI antibodies against A/turkey/Turkey/01/2005 H5N1 virus strain
    End point description
    Mean Geometric Change is defined as the geometric mean of the within-subject ratios of the post vaccination reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer (i.e. post-vaccination divided by pre-vaccination titer). Data for Day 192 are presented under Primary Outcome Measures.
    End point type
    Secondary
    End point timeframe
    Day 182 and Day 364
    End point values
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group GSK1562902A Group
    Number of subjects analysed
    41
    26
    32
    99
    Units: Subjects
        A/turkey/Turkey/1/2005 H5N1.HA [Day 182]
    33
    21
    29
    83
        A/turkey/Turkey/1/2005 H5N1.HA [Day 364]
    41
    26
    32
    99
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Serious Adverse Events: From Day 0 to Day 364; Solicited local and general symptoms: During the 7-day (Days 0-6) post-vaccination period; Unsolicited adverse events: During the 84-day (Days 0-84) post-vaccination period.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    15.1
    Reporting groups
    Reporting group title
    GSK1562902A 6 to 12 M Group
    Reporting group description
    		 -

    Reporting group title
    GSK1562902A 12 to 24 M Group
    Reporting group description
    		 -

    Reporting group title
    GSK1562902A 24 to 36 M Group
    Reporting group description
    		 -

    Serious adverse events
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    5 / 46 (10.87%)
    4 / 34 (11.76%)
    0 / 33 (0.00%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Injury, poisoning and procedural complications
    Burns second degree
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Diarrhoea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Asthma
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 46 (4.35%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Wheezing
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Upper respiratory tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 46 (2.17%)
    2 / 34 (5.88%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Bronchiolitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 46 (2.17%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastritis viral
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis rotavirus
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis viral
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lobar pneumonia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    2 / 34 (5.88%)
    0 / 33 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    		 GSK1562902A 6 to 12 M Group GSK1562902A 12 to 24 M Group GSK1562902A 24 to 36 M Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    45 / 46 (97.83%)
    32 / 34 (94.12%)
    33 / 33 (100.00%)
    Vascular disorders
    Haematoma
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    General disorders and administration site conditions
    Pain
         subjects affected / exposed
    27 / 46 (58.70%)
    19 / 34 (55.88%)
    21 / 33 (63.64%)
         occurrences all number
    45
    33
    45
    Swelling
         subjects affected / exposed
    6 / 46 (13.04%)
    6 / 34 (17.65%)
    1 / 33 (3.03%)
         occurrences all number
    8
    8
    2
    Pyrexia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    31 / 46 (67.39%)
    20 / 34 (58.82%)
    22 / 33 (66.67%)
         occurrences all number
    45
    39
    40
    Chest discomfort
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Injection site haematoma
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Injection site induration
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Injection site rash
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Injection site scab
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
    alternative assessment type: Non-systematic
         subjects affected / exposed
    9 / 46 (19.57%)
    8 / 34 (23.53%)
    2 / 33 (6.06%)
         occurrences all number
    13
    8
    6
    Rhinorrhoea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    11 / 46 (23.91%)
    2 / 34 (5.88%)
    3 / 33 (9.09%)
         occurrences all number
    12
    2
    4
    Asthma
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Choking sensation
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Dyspnoea
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Epistaxis
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Increased upper airway secretion
         subjects affected / exposed
    1 / 46 (2.17%)
    2 / 34 (5.88%)
    1 / 33 (3.03%)
         occurrences all number
    1
    2
    2
    Pharyngeal inflammation
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Wheezing
         subjects affected / exposed
    0 / 46 (0.00%)
    2 / 34 (5.88%)
    0 / 33 (0.00%)
         occurrences all number
    0
    2
    0
    Psychiatric disorders
    Irritability
         subjects affected / exposed
    35 / 46 (76.09%)
    23 / 34 (67.65%)
    15 / 33 (45.45%)
         occurrences all number
    63
    46
    30
    Investigations
    Body temperature increased
         subjects affected / exposed
    1 / 46 (2.17%)
    2 / 34 (5.88%)
    0 / 33 (0.00%)
         occurrences all number
    1
    2
    0
    Injury, poisoning and procedural complications
    Arthropod bite
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Contusion
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    1 / 33 (3.03%)
         occurrences all number
    0
    1
    1
    Foreign body
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Ligament sprain
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Tooth fracture
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Upper limb fracture
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Somnolence
         subjects affected / exposed
    22 / 46 (47.83%)
    18 / 34 (52.94%)
    12 / 33 (36.36%)
         occurrences all number
    34
    27
    22
    Ear and labyrinth disorders
    Ear pain
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Eye disorders
    Chalazion
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Conjunctivitis
         subjects affected / exposed
    2 / 46 (4.35%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    2
    0
    2
    Eye pain
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    1 / 46 (2.17%)
    1 / 34 (2.94%)
    2 / 33 (6.06%)
         occurrences all number
    1
    1
    2
    Vomiting
    alternative assessment type: Non-systematic
         subjects affected / exposed
    17 / 46 (36.96%)
    11 / 34 (32.35%)
    10 / 33 (30.30%)
         occurrences all number
    30
    15
    12
    Teething
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 46 (10.87%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    7
    1
    0
    Abdominal pain
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    0
    0
    1
    Constipation
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Skin and subcutaneous tissue disorders
    Dermatitis diaper
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 46 (0.00%)
    3 / 34 (8.82%)
    0 / 33 (0.00%)
         occurrences all number
    0
    3
    0
    Eczema
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 46 (2.17%)
    3 / 34 (8.82%)
    0 / 33 (0.00%)
         occurrences all number
    1
    3
    0
    Blister
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Dry skin
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Erythema
         subjects affected / exposed
    13 / 46 (28.26%)
    6 / 34 (17.65%)
    3 / 33 (9.09%)
         occurrences all number
    16
    7
    5
    Pruritus
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Rash
         subjects affected / exposed
    3 / 46 (6.52%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    3
    0
    1
    Rash macular
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Swelling face
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Urticaria
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 34 (0.00%)
    3 / 33 (9.09%)
         occurrences all number
    0
    0
    3
    Infections and infestations
    Upper respiratory tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    9 / 46 (19.57%)
    5 / 34 (14.71%)
    12 / 33 (36.36%)
         occurrences all number
    11
    6
    14
    Nasopharyngitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 46 (6.52%)
    5 / 34 (14.71%)
    2 / 33 (6.06%)
         occurrences all number
    3
    8
    2
    Rhinitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 46 (10.87%)
    1 / 34 (2.94%)
    2 / 33 (6.06%)
         occurrences all number
    6
    1
    2
    Bronchiolitis
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Candidiasis
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Croup infectious
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Hand-foot-and-mouth disease
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Otitis media
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    1 / 33 (3.03%)
         occurrences all number
    0
    1
    2
    Roseola
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    0 / 33 (0.00%)
         occurrences all number
    1
    0
    0
    Sinusitis
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    0 / 33 (0.00%)
         occurrences all number
    0
    1
    0
    Tonsillitis
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 34 (2.94%)
    2 / 33 (6.06%)
         occurrences all number
    0
    1
    2
    Varicella
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    1
    0
    1
    Viral rash
         subjects affected / exposed
    1 / 46 (2.17%)
    0 / 34 (0.00%)
    1 / 33 (3.03%)
         occurrences all number
    1
    0
    1
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    22 / 46 (47.83%)
    18 / 34 (52.94%)
    14 / 33 (42.42%)
         occurrences all number
    33
    30
    24

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    24 Jan 2011
    Amendment 1 The former version of the protocol was published in two versions, due to a tehnical problem. The first version contained errors in the tables of intensity. This version was submitted in Singapore. The second version contained errors in the vaccine tables, where commas where left out in the volumes. This version was submitted in Australia. This Amendment is based on the latter version of the final protocol. Therefore, track changes will not be found in the amendment, although a difference exists with the version submitted in Singapore. The changes have been brought to the tables as explained under Section 8.2.2.2.1. Additional changes have been brought to clarify the contents of the vials and vaccine doses.
    16 Jun 2011
    Amendment 2 The protocol was amended to exclude subjects who had a past medical history of infection with a H5N1 virus or vaccination with a H5N1 vaccine. Exclusion criteria were updated accordingly. In addition, procedures for collection of medically-attended adverse events between Day 203 and Day 364 have been clarified.
    04 Nov 2011
    Amendment 3 With Amendment 3, the protocol was adjusted to document that the age stratification ratio of 2:1:1 for children 6 to 11 months, 12 to 23 months, and 24 to 35 months of age, respectively, was not be maintained due to recruitment difficulties. The overall subjects enrolment goal were not change.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 17:03:40 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA